A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Incyte Corp stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 235,849 shares of INCY stock, worth $16.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
235,849
Previous 247,207 4.59%
Holding current value
$16.8 Million
Previous $15 Million 4.03%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$57.33 - $68.61 $651,154 - $779,272
-11,358 Reduced 4.59%
235,849 $15.6 Million
Q2 2024

Aug 12, 2024

BUY
$51.18 - $63.75 $1.18 Million - $1.47 Million
23,088 Added 10.3%
247,207 $15 Million
Q1 2024

May 09, 2024

BUY
$56.55 - $66.59 $2.74 Million - $3.22 Million
48,380 Added 27.53%
224,119 $12.8 Million
Q4 2023

Feb 08, 2024

SELL
$52.16 - $64.19 $63,530 - $78,183
-1,218 Reduced 0.69%
175,739 $11 Million
Q3 2023

Nov 07, 2023

BUY
$57.77 - $65.93 $1.19 Million - $1.36 Million
20,588 Added 13.17%
176,957 $10.2 Million
Q2 2023

Aug 09, 2023

BUY
$60.95 - $75.51 $548,671 - $679,741
9,002 Added 6.11%
156,369 $9.73 Million
Q1 2023

May 08, 2023

BUY
$70.23 - $86.01 $1.01 Million - $1.23 Million
14,339 Added 10.78%
147,367 $10.7 Million
Q4 2022

Feb 07, 2023

BUY
$67.18 - $84.11 $788,558 - $987,283
11,738 Added 9.68%
133,028 $10.7 Million
Q3 2022

Nov 01, 2022

BUY
$66.18 - $82.86 $806,734 - $1.01 Million
12,190 Added 11.17%
121,290 $8.08 Million
Q2 2022

Aug 04, 2022

BUY
$66.18 - $83.18 $418,985 - $526,612
6,331 Added 6.16%
109,100 $8.29 Million
Q1 2022

May 09, 2022

BUY
$66.02 - $79.71 $925,468 - $1.12 Million
14,018 Added 15.79%
102,769 $8.16 Million
Q4 2021

Feb 07, 2022

BUY
$63.34 - $74.11 $238,158 - $278,653
3,760 Added 4.42%
88,751 $6.57 Million
Q3 2021

Nov 04, 2021

BUY
$68.67 - $84.02 $937,826 - $1.15 Million
13,657 Added 19.15%
84,991 $5.85 Million
Q2 2021

Aug 06, 2021

BUY
$79.87 - $87.53 $525,864 - $576,297
6,584 Added 10.17%
71,334 $6 Million
Q1 2021

May 06, 2021

BUY
$76.02 - $100.5 $720,821 - $952,941
9,482 Added 17.16%
64,750 $5.26 Million
Q4 2020

Feb 09, 2021

BUY
$80.74 - $97.7 $260,870 - $315,668
3,231 Added 6.21%
55,268 $4.81 Million
Q3 2020

Nov 10, 2020

BUY
$85.07 - $109.69 $705,740 - $909,988
8,296 Added 18.97%
52,037 $4.67 Million
Q2 2020

Aug 06, 2020

BUY
$74.18 - $108.93 $539,511 - $792,247
7,273 Added 19.94%
43,741 $4.55 Million
Q1 2020

May 11, 2020

BUY
$63.18 - $85.97 $43,151 - $58,717
683 Added 1.91%
36,468 $2.67 Million
Q4 2019

Feb 05, 2020

BUY
$73.04 - $95.72 $301,655 - $395,323
4,130 Added 13.05%
35,785 $2.79 Million
Q3 2019

Nov 12, 2019

BUY
$72.82 - $86.52 $98,161 - $116,628
1,348 Added 4.45%
31,655 $2.35 Million
Q2 2019

Aug 08, 2019

BUY
$73.52 - $88.7 $402,154 - $485,189
5,470 Added 22.02%
30,307 $2.58 Million
Q1 2019

Apr 26, 2019

BUY
$63.56 - $88.17 $177,332 - $245,994
2,790 Added 12.65%
24,837 $2.14 Million
Q4 2018

Feb 08, 2019

SELL
$58.5 - $69.94 $117,936 - $140,999
-2,016 Reduced 8.38%
22,047 $1.5 Million
Q3 2018

Nov 13, 2018

SELL
$61.75 - $74.23 $3.48 Million - $4.18 Million
-56,316 Reduced 70.06%
24,063 $1.66 Million
Q2 2018

Aug 09, 2018

BUY
$60.85 - $83.98 $1.57 Million - $2.17 Million
25,795 Added 47.26%
80,379 $5.39 Million
Q1 2018

May 02, 2018

BUY
$83.06 - $100.98 $1.96 Million - $2.39 Million
23,644 Added 76.42%
54,584 $4.55 Million
Q4 2017

Feb 06, 2018

SELL
$93.56 - $116.6 $2,526 - $3,148
-27 Reduced 0.09%
30,940 $3.12 Million
Q3 2017

Nov 01, 2017

BUY
$109.15 - $138.27 $3.38 Million - $4.28 Million
30,967
30,967 $3.62 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.